Navidea Biopharmaceuticals Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Navidea Biopharma (NAVB) Reports Q1 Loss of $0.13
May 14, 2020 4:25 PM EDTNavidea Biopharma (NYSE: NAVB) reported Q1 EPS of ($0.13), versus ($0.24) reported last year. Revenue for the quarter came in at $155.66 thousand, versus $41.62 thousand reported last year.
First Quarter 2020 Highlights and Subsequent Events
Continued with double-digit subject enrollment in the Companys NAV3-31 Phase 2b study in rheumatoid arthritis (RA) and completed enrollment of subjects in Arms 1 and 2.Continued enrollment in the Investigator Initiated Phase 2 trial being run at the Massachusetts General Hospital evaluating Tc99m tilmanocept uptake in atherosclerotic plaques of HIV-infected individuals.Announced extension by the U.S. Patent and... More